MedTrace Logo

Poziotinib in Stage IV Lung Adenocarcinoma With HER2 Mutation (KASTT001)

NCT02979821 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2018-05-24

No results posted yet for this study

Summary

In this trial, treatment efficacy and safety of Poziotinib will be assessed in patients with stage IV lung adenocarcinoma harboring HER2 mutation.

Conditions

  • HER2 Gene Mutation
  • Adenocarcinoma Lung Stage IV

Interventions

DRUG

Poziotinib

A cycle of study treatment is defined as 28 days.

Sponsors & Collaborators

  • Konkuk University Medical Center

    collaborator OTHER

  • Kyungpook National University Hospital

    collaborator OTHER

  • Kosin University Gospel Hospital

    collaborator OTHER

  • Chonnam National University Hospital

    collaborator OTHER

  • Chungnam National University Hospital

    collaborator OTHER

  • Korean Association for the Study of Targeted Therapy

    lead OTHER

Principal Investigators

  • Kye-Young, Lee, MD, PhD · Kunkok University Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-10-31
Primary Completion
2017-12-31
Completion
2017-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02979821 on ClinicalTrials.gov